For patients with SCLC, little progress has been made in efficacious predictive biomarkers including programmed death-ligand 1 (PD-L1).10 Therefore, identification of patients who may benefit from immunotherapy is urgently needed. The gene discussed is CD274; the disease is small cell lung carcinoma.